ORIC Pharmaceuticals, Inc. ORIC NASDAQ

ORIC Pharmaceuticals, Inc. (ORIC) reported total assets of $411M and total liabilities of $26.64M for fiscal year 2025, resulting in total equity of $384.36M.

The company held $281.49M in cash and short-term investments. Total debt stood at $11.55M, with net debt of $-34.12M. The Debt-to-Equity (D/E) ratio was 0.03 (conservative).

Current ratio is 14.13, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0.03, current ratio of 14.13 — balance sheet is strong
• MOAT (40/100) — Total assets $411M and equity $384.36M support the company's competitive scale
• VALUE (100/100) — Debt-to-Equity 0.03 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 57/100 with 3/7 criteria passed.

CELC

Celcuity Inc.

$123.47

+2.17%

EWTX

Edgewise Therapeutics, Inc.

$33.70

+1.63%

ELVN

Enliven Therapeutics, Inc.

$43.95

-2.01%

MLYS

Mineralys Therapeutics, Inc.

$30.42

+11.35%

PHVS

Pharvaris N.V.

$29.14

+1.60%

CGEM

Cullinan Oncology, Inc.

$14.95

+4.18%

CCCC

C4 Therapeutics, Inc.

$2.89

+4.90%

IMRX

Immuneering Corporation

$5.75

+6.28%